

# TAYSIDE PRESCRIBER

## Tayside DTC Supplement No 64

December 2006

*Produced by NHS Tayside Drug and Therapeutics Committee*

### SMC Advice issued in December 2006

Medicine	Indication	Local recommendation category	Comments and useful links
Adalimumab (Humira®)	Severe active ankylosing spondylitis	HOSPITAL ONLY (Rheumatology Clinic)	2 <sup>nd</sup> -line TNF-antagonist ie patients unable to tolerate etanercept <a href="#">SMC advice</a> <a href="#">SPC link</a>
Gemcitabine (Gemzar®) - <i>resubmission</i>	Metastatic breast cancer	HOSPITAL ONLY	Update to protocol awaited <a href="#">SMC advice</a> <a href="#">SPC link</a>
Lanreotide (Somatuline® LA) – <i>non-submission</i>	Thyrotrophic adenomas	<b>Not recommended</b>	<a href="#">SMC advice</a>
Methotrexate injection (Metoject®) – <i>abbreviated submission</i>	Severe active rheumatoid arthritis in adults	Pending update of parenteral methotrexate policy	<a href="#">SMC advice</a>
Mitotane (Lysodren®)	Advanced adrenal cortical carcinoma	<b>Not recommended</b>	<a href="#">SMC advice</a>
Natalizumab (Tysabri®)	Active relapsing remitting multiple sclerosis (RRMS)	<b>Not recommended</b>	<a href="#">SMC advice</a>
Pregabalin (Lyrica®) - <i>non-submission</i>	Generalised anxiety disorder in adults	<b>Not recommended</b>	<a href="#">SMC advice</a>
Rasagiline (Azilect®) - <i>resubmission</i>	Idiopathic Parkinson's disease as monotherapy	<b>Not recommended</b>	<a href="#">SMC advice</a>
Rasagiline (Azilect®) - <i>resubmission</i>	Idiopathic Parkinson's disease as adjunct therapy	<b>Not recommended</b>	<a href="#">SMC advice</a>
Rituximab (MabThera®)	Maintenance therapy for relapsed/refractory follicular lymphoma	HOSPITAL ONLY	Update to protocol awaited <a href="#">SMC advice</a> <a href="#">SPC link</a>
Temozolomide (Temodal®) - <i>resubmission</i>	Newly diagnosed glioblastoma multiforme (GBM)	HOSPITAL ONLY	Update to protocol awaited <a href="#">SMC advice</a> <a href="#">SPC link</a>
Triptorelin 11.25mg (Decapeptyl SR®) – <i>abbreviated submission</i>	Precocious puberty	HOSPITAL ONLY (Paediatric Endocrine Clinic)	Alternative to off-label goserelin <a href="#">SMC advice</a> <a href="#">SPC link</a>

## TAPG Update

	TAPG section	Drug(s)/topic	Changes
4.1	Hypnotics and anxiolytics	Lormetazepam Zopiclone	First-choice hypnotic changed from lormetazepam to zopiclone on the basis of cost-effectiveness (clinical equivalence at reduced cost). Lormetazepam removed from formulary.
10.1	Rheumatic disease and gout	NSAIDs Osteoarthritis algorithm	Incorporation of recent CHM advice on cardiovascular safety of non-selective NSAIDs.

## Status of NICE advice in Scotland

NICE produce three different types of advice which have differing status in NHS Scotland as follows:

Advice type	Status in Scotland
Multiple Technology Assessment (MTA)	NHS QIS-validated MTAs supersede SMC advice
Single Technology Assessment (STA)	No formal status.
Clinical Guidelines	No formal status

[Click here](#) for further details.

## Forthcoming SMC Advice

**Contact details:** Local implementation of SMC recommendations is being taken forward by the Tayside Medicines Unit - contact Jan Jones, Principal Pharmacist - Pharmacoeconomics ([janjones@nhs.net](mailto:janjones@nhs.net)) if you have any queries in relation to the introduction of new drugs within NHS Tayside.

This bulletin is based on evidence available to the Tayside Medicines Unit at time of publication and is covered by the Disclaimer and Terms & Conditions of use and access to the NHS Tayside Drug and Therapeutics Committee website ([www.nhstaysideadtc.scot.nhs.uk](http://www.nhstaysideadtc.scot.nhs.uk)).